Equity · Healthcare
ABUS
NASDAQArbutus Biopharma (ABUS)
The line runs 4.60 USD on 12 August through 3.72 USD on 9 November, on a scale from 3.5 to 5.5. Days the market did not trade hold the previous close, flat.
- Market cap
- 722.1M USD
- P/E (TTM)
- 4.6
- Revenue, year to Dec 2025
- 14.1M USD
- EPS, diluted, year to Dec 2025
- −0.17 USD
- 52-week range
- 3.65 USD – 5.20 USD
- Avg volume
- 373.4K
as of Nov 6, 2026
Have Arbutus Biopharma (ABUS) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, no Arbutus Biopharma insider bought or sold shares on the open market; all 12 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).
Form 4, 90 days to 10 Nov 2026, newest Form 4 filing 1 Oct 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 01 Oct 2026 | Androski LindsayPresident and CEO | Other | 24,655 | 123K USD |
| 01 Oct 2026 | Sawhney RogerDirector | Other | 17,142 | 86K USD |
| 01 Oct 2026 | Nguyen TuanChief Financial Officer | Other | 48,081 | 240K USD |
| 01 Oct 2026 | Beardsley Robert ADirector | Other | 17,948 | 90K USD |
| 18 Sep 2026 | Androski LindsayPresident and CEO | Option exercise | 126,864 | 418K USD |
| 18 Sep 2026 | Androski LindsayPresident and CEO | Tax withheld | 82,527 | 418K USD |
| 18 Sep 2026 | Beardsley Robert ADirector | Option exercise | 131,333 | 502K USD |
| 18 Sep 2026 | Beardsley Robert ADirector | Tax withheld | 99,057 | 502K USD |
| 18 Sep 2026 | Sawhney RogerDirector | Option exercise | 131,333 | 510K USD |
| 18 Sep 2026 | Sawhney RogerDirector | Tax withheld | 100,508 | 510K USD |
| 18 Sep 2026 | Nguyen TuanChief Financial Officer | Option exercise | 293,100 | 1.0M USD |
| 18 Sep 2026 | Nguyen TuanChief Financial Officer | Tax withheld | 206,637 | 1.0M USD |
Which funds hold Arbutus Biopharma (ABUS)?
5 of the 45 institutional funds we track reported a Arbutus Biopharma position for the quarter ended 30 Jun 2026 — a combined 6.6M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Man Group | New position | 473,467 | 2.3M USD | |
| Citadel Advisors | Trimmed | 404,696 | 1.9M USD | −40.2% |
| D. E. Shaw & Co. | Added | 381,863 | 1.8M USD | +166.7% |
| Two Sigma Investments | New position | 84,986 | 408K USD | |
| AQR Capital Management | Added | 31,741 | 152K USD | +33.3% |
| Balyasny Asset Management | Exited | |||
| Millennium Management | Exited |
What has been filed or recorded for Arbutus Biopharma (ABUS)?
The filings we hold for Arbutus Biopharma, newest first: 5 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 14 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 15,982 shares | 66K USD notional · 0.008% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 2 shares | 8 USD notional · <0.001% of shares out |
| 07 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,000 shares | 4K USD notional · 0.001% of shares out |
| 05 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,190,578 shares | 5.3M USD notional · 0.602% of shares out |
| 02 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,641,844 shares | 12.0M USD notional · 1.335% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.03 USD | Revenue $1M |
| 30 Jun 2026 | Financials | Total assets | 274.0M USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 258.7M USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.87 USD | Revenue $179M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.17 USD | Revenue $14M |
| 31 Dec 2025 | Financials | Revenue | 14.1M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −33.5M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.17 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.04 USD | Revenue $1M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.01 USD | Revenue $11M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.13 USD | Revenue $2M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −0.38 USD | Revenue $6M |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −0.10 USD | Revenue $1M |
What do people ask about Arbutus Biopharma (ABUS)?
What did Arbutus Biopharma shares close at?3.72
Arbutus Biopharma closed at 3.72 USD on 9 Nov 2026, up 1.92% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Arbutus Biopharma’s market cap?722.1M
Arbutus Biopharma is worth 722.1M USD by market value as of 6 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Arbutus Biopharma’s P/E ratio?4.6
Arbutus Biopharma has a price-to-earnings ratio of 4.6, as of 6 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Arbutus Biopharma’s revenue?14.1M
Arbutus Biopharma reported revenue of 14.1M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Arbutus Biopharma insiders bought or sold shares recently?12 filings
In the 90 days to 10 Nov 2026, no Arbutus Biopharma insider bought or sold shares on the open market; all 12 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4). See Insiders
Which funds own Arbutus Biopharma?5 of 45
5 of the 45 funds we track reported a Arbutus Biopharma position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Man Group, Citadel Advisors and D. E. Shaw & Co. See Funds
When did Arbutus Biopharma last report earnings?−0.03
Arbutus Biopharma last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.03 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings